Top Story Today
The Most Expensive 0.013 in Biotech
A gap of 0.013 in p-value just separated Regeneron from a potential blockbuster and a very expensive disappointment. Its LAG-3 combo fianlimab plus cemiplimab showed 11.5 months of progression-free survival versus Keytruda's 6.4 months in advanced melanoma, but the hazard ratio's confidence interval crossed 1.0, meaning the math couldn't rule out chance. Shares dropped roughly 12%. Analysts slashed projected peak sales from their models, and Regeneron's oncology ambitions look increasingly fragile after multiple late-stage misses.
Why it matters: A second major Phase 3 oncology failure compounds pressure on Regeneron's checkpoint inhibitor strategy and raises broader questions about whether LAG-3 monotherapy combos can ever dethrone Keytruda in head-to-head competition.
Read more →Deals and M&A
Regeneron's $2.3B Rebound: Betting on a Cancer Weapon That Doesn't Exist Yet
On the same day as its melanoma flop, Regeneron paid $125 million upfront (with up to roughly $2.2 billion in milestones) for access to Parabilis Medicines' Antibody-Helicon Conjugates, an entirely unproven drug class. The technology uses stabilized cell-penetrating peptides to hit "undruggable" targets inside cancer cells. No clinical candidates exist yet, but the deal signals Regeneron is diversifying hard away from checkpoint-inhibitor dependence.
Read more →A 107-Year-Old Italian Pharma Just Dropped $4.1B to Break Into America
Angelini Pharma, a family-owned Italian company, agreed to buy Catalyst Pharmaceuticals for $4.1 billion in cash, roughly three times its own annual revenue. The deal instantly gives Angelini a U.S. rare disease engine generating $589 million a year, anchored by Firdapse for Lambert-Eaton syndrome and Agamree for Duchenne muscular dystrophy.
Read more →Bayer Pays Up to $2.45B for an Eye Drug That Doesn't Lower Pressure at All
Perfuse Therapeutics raised just $11 million total before Bayer agreed to acquire it for $300 million upfront and up to $2.15 billion in milestones. The prize: PER-001, a biodegradable eye implant that targets blood flow instead of eye pressure, showing early signs of actually reversing glaucoma damage. If it works, it would be the first disease-modifying glaucoma therapy ever.
Read more →Clinical and Regulatory
Moderna's Flu Vaccine Got Rejected. Then It Got Un-Rejected.
The FDA refused to review Moderna's mRNA flu vaccine in February, then reversed course roughly a week after a high-priority meeting, setting an August 5 review deadline. The initial rejection centered on comparator choice in seniors. The reversal keeps alive Moderna's post-COVID diversification strategy and its pipeline of combination respiratory vaccines, though the agency will apply a "higher bar" for the senior population.
Read more →The FDA Just Made Copycat Biologics Way Cheaper to Develop
The FDA effectively eliminated mandatory comparative efficacy trials for most biosimilars and cut PK study costs by up to 50%. With biologics accounting for roughly 5% of U.S. prescriptions but 50% of drug spending, the streamlined pathway could flood the market with cheaper alternatives as blockbusters like Keytruda and Stelara lose patent protection in coming years.
Read more →CRISPR Without the Scissors: Epicrispr Silences a Disease Gene in Humans
Epicrispr reported the first human data for EPI-321, a CRISPR-based therapy that silences disease genes without cutting DNA. Patients with FSHD (a muscular dystrophy with zero approved treatments) showed early functional improvements and no serious side effects. It's the first CRISPR epigenetic therapy ever tested in muscular dystrophy, opening a potential new playbook for dominant genetic diseases.
Read more →AI and Discovery
An AI Designed Both the Target and the Drug. It Just Worked in Humans.
Insilico Medicine's rentosertib, a drug where AI picked both the biological target and designed the molecule, posted Phase 2a results in IPF showing a 98.4 mL gain in lung capacity versus a 20.3 mL decline on placebo. The results, published in Nature Medicine, represent one of the strongest clinical validations yet that end-to-end AI drug discovery can produce real human benefit.
Read more →Lilly Bets $2.75B That AI-Designed Drugs Are the Future
Eli Lilly expanded its Insilico Medicine partnership to a potential $2.75 billion, licensing AI-designed preclinical candidates and launching joint R&D programs. It's Lilly's third deal with Insilico in three years, each dramatically larger than the last, signaling that AI-native drug discovery is moving from side project to core strategy at one of pharma's biggest companies.
Read more →Funding and Financings
Wall Street Believes in Brain Drugs Again: Seaport's $255M IPO
Seaport Therapeutics priced its upsized IPO at $18 per share, raising $255 million at the top of its range. Built by the team that sold Karuna Therapeutics to Bristol Myers Squibb for $14 billion, Seaport is developing oral versions of proven brain-active molecules for depression and anxiety. The blockbuster debut signals renewed investor appetite for CNS biotech after years of skepticism.
Read more →